Venn Life Sciences Holdings Share Price London S.E.
Equities
GB00B9275X97
Biotechnology & Medical Research
Sales 2023 | 56.04M 70.01M 5.6B | Sales 2024 * | 62.91M 78.59M 6.29B | Capitalization | 192M 240M 19.22B |
---|---|---|---|---|---|
Net income 2023 | 16M 19.99M 1.6B | Net income 2024 * | 8M 9.99M 800M | EV / Sales 2023 | 2.88 x |
Net cash position 2023 * | 34.79M 43.46M 3.48B | Net cash position 2024 * | 43.8M 54.72M 4.38B | EV / Sales 2024 * | 2.36 x |
P/E ratio 2023 |
10.1
x | P/E ratio 2024 * |
22.7
x | Employees | - |
Yield 2023 * |
1.43% | Yield 2024 * |
0.83% | Free-Float | 60.8% |
Latest transcript on Venn Life Sciences Holdings
Managers | Title | Age | Since |
---|---|---|---|
Yamin Khan
CEO | Chief Executive Officer | 55 | 12/10/21 |
Ian O'Connell
FOU | Founder | 37 | 31/01/11 |
Cathal Friel
FOU | Founder | 59 | 31/01/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 07/06/22 | |
Cathal Friel
FOU | Founder | 59 | 31/01/11 |
Brendan Buckley
FOU | Founder | 73 | 30/11/18 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |